139 related articles for article (PubMed ID: 24240316)
1. Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1.
Pontillo A; Da Silva RC; Moura R; Crovella S
Hum Vaccin Immunother; 2014; 10(2):512-8. PubMed ID: 24240316
[TBL] [Abstract][Full Text] [Related]
2. Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy.
Reis EC; da Silva LT; da Silva WC; Rios A; Duarte AJ; Oshiro TM; Crovella S; Pontillo A
Hum Vaccin Immunother; 2018; 14(8):1995-2002. PubMed ID: 29641325
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.
Moura Rodrigues R; Plana M; Garcia F; Zupin L; Kuhn L; Crovella S
Immunol Res; 2016 Dec; 64(5-6):1207-1215. PubMed ID: 27704462
[TBL] [Abstract][Full Text] [Related]
4. Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment.
Moura R; Pontillo A; D'Adamo P; Pirastu N; Campos Coelho A; Crovella S
J Int AIDS Soc; 2014; 17(1):18938. PubMed ID: 24433985
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment.
Segat L; Brandão LAC; Guimarães RL; Pontillo A; Athanasakis E; de Oliveira RM; Arraes LC; de Lima Filho JL; Crovella S
Vaccine; 2010 Mar; 28(10):2201-2206. PubMed ID: 20056178
[TBL] [Abstract][Full Text] [Related]
6. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?
da Silva LT; Santillo BT; de Almeida A; Duarte AJDS; Oshiro TM
Front Immunol; 2018; 9():2993. PubMed ID: 30619346
[TBL] [Abstract][Full Text] [Related]
7. Treating HIV-1 infection with dendritic cells.
Connolly NC; Colleton BA; Rinaldo CR
Curr Opin Mol Ther; 2007 Aug; 9(4):353-63. PubMed ID: 17694448
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based human immunodeficiency virus vaccine.
Rinaldo CR
J Intern Med; 2009 Jan; 265(1):138-58. PubMed ID: 19093966
[TBL] [Abstract][Full Text] [Related]
9. TRIM5 gene polymorphisms in HIV-1-infected patients and healthy controls from Northeastern Brazil.
Celerino da Silva R; Coelho AV; Arraes LC; Brandão LA; Crovella S; Guimarães RL
Immunol Res; 2016 Dec; 64(5-6):1237-1242. PubMed ID: 27388872
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association study implicates PARD3B-based AIDS restriction.
Troyer JL; Nelson GW; Lautenberger JA; Chinn L; McIntosh C; Johnson RC; Sezgin E; Kessing B; Malasky M; Hendrickson SL; Li G; Pontius J; Tang M; An P; Winkler CA; Limou S; Le Clerc S; Delaneau O; Zagury JF; Schuitemaker H; van Manen D; Bream JH; Gomperts ED; Buchbinder S; Goedert JJ; Kirk GD; O'Brien SJ
J Infect Dis; 2011 May; 203(10):1491-502. PubMed ID: 21502085
[TBL] [Abstract][Full Text] [Related]
11. DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.
de Goede AL; Andeweg AC; van den Ham HJ; Bijl MA; Zaaraoui-Boutahar F; van IJcken WF; Wilgenhof S; Aerts JL; Gruters RA; Osterhaus AD;
Vaccine; 2015 Jun; 33(25):2922-9. PubMed ID: 25913415
[TBL] [Abstract][Full Text] [Related]
12. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
14. DC-based immunotherapy as strategy to purge the HIV reservoir?
Søgaard OS
EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
[No Abstract] [Full Text] [Related]
15. A therapeutic dendritic cell-based vaccine for HIV-1 infection.
García F; Climent N; Assoumou L; Gil C; González N; Alcamí J; León A; Romeu J; Dalmau J; Martínez-Picado J; Lifson J; Autran B; Costagliola D; Clotet B; Gatell JM; Plana M; Gallart T;
J Infect Dis; 2011 Feb; 203(4):473-8. PubMed ID: 21233310
[TBL] [Abstract][Full Text] [Related]
16. Future considerations for dendritic cell immunotherapy against chronic viral infections.
Atanley E; van Drunen Littel-van den Hurk S
Expert Rev Clin Immunol; 2014 Jun; 10(6):801-13. PubMed ID: 24734867
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 induces NALP3-inflammasome expression and interleukin-1β secretion in dendritic cells from healthy individuals but not from HIV-positive patients.
Pontillo A; Silva LT; Oshiro TM; Finazzo C; Crovella S; Duarte AJ
AIDS; 2012 Jan; 26(1):11-8. PubMed ID: 21971358
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.
de Goede AL; van Deutekom HW; Vrancken B; Schutten M; Allard SD; van Baalen CA; Osterhaus AD; Thielemans K; Aerts JL; Keşmir C; Lemey P; Gruters RA
AIDS; 2013 Nov; 27(17):2679-89. PubMed ID: 24149085
[TBL] [Abstract][Full Text] [Related]
19. The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.
Mohamed H; Miller V; Jennings SR; Wigdahl B; Krebs FC
J Immunol Res; 2020; 2020():9470102. PubMed ID: 32537473
[TBL] [Abstract][Full Text] [Related]
20. Advances in dendritic cell immunotherapies for HIV-1 infection.
Miller E; Bhardwaj N
Expert Opin Biol Ther; 2014 Nov; 14(11):1545-9. PubMed ID: 25143151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
